2026 年 4 月 17–22 日 · San Diego · 共 2429 条
7 人 · 12 条 · 8 篇摘要
围手术期 IO 已经是 MNC 主战场。中国 PD-L1 抗体（adebrelimab）用 EFS 数据挤进同一张桌子。下一步不是再报一个缓解率，而是停药能不能由 MRD 决定、双抗能不能在新辅助里超过单抗。
| 药 / 试验 | 读数 | 场景 |
|---|---|---|
| adebrelimabadebrelimab#NSCLC | 围手术期 EFS HR 0.52 | 可切除 NSCLC |
| CheckMate 77Tnivolumab#LIQUIDBIOPSY#NSCLC | ctDNA 清除者才有高 pCR | 与 MRD 方向同一组读数 |
TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastases
Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella
Perioperative adebrelimab (A) plus chemotherapy (chemo) in resectable stage II-III NSCLC: Phase 3 EFS interim analysis (IA) and molecular residual disease (MRD) analysis
Yi-Long Wu, Wen-Zhao Zhong, Li-Xu Yan, Keneng Chen, Wanpu Yan, Yongzhong Luo, Wenxiang Wang, Wenqun Xing, Xiaolong Yan, Lin Wu, Feng Yao, Dongsheng Yue, Naiquan Mao, Yu Qi, Bentong Yu, Jianji Guo, Jindan Kai, Yuejun Chen, Hui Wang, Qin Zhang, Lunxu Liu, Honghai Wang, Yuanyuan Ji, Yongtao Han, Yongxiang Song, Jianjun Xu, Wei Guo, Hongxu Liu, Di Ge, Hecheng Li, XiuJuan Qu, Jifang Yao, Junfeng Liu, Tingyan Zhong, Yanhua Huang, Li Song, Wei Shi
Combination of risvutatug rezetecan and adebrelimab in previously treated advanced nsq-NSCLC without actionable genomic alterations: Results from ARTEMIS-101, a phase 1 study
Hua Zhong, Haifeng Liu, Wei Zheng, Linlin Wang, Baogang Liu, Fangling Ning, Yongzhong Luo, Qiming Wang, Weiliang Zhu, Jianying Zhou, Qingwei Zhao, Ruoyu Wang, Xiang Li, Juan Li, Runbo Zhong, Yizhou Jin, Xiangru Mao, Jing Wang, Qingyuan Liu, Xiaoqing Zhang
Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)
Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Maya Khalil, Brian S. Henick, James Moon, Pasarlai Ahmadzai, Michael LeBlanc, Daniel R. Carrizosa, Paul J. Hesketh, Ellen V. Sigal, Jeff Allen, Andreas N. Saltos, Bryan A. Faller, Roy S. Herbst, Charles D. Blanke, Jhanelle E. Gray
RASolve 301: A Phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC
Ferdinandos Skoulidis, Kathryn C. Arbour, Sanjay Popat, Colin R. Lindsay, Hidehito Hironouchi, Gérard Zalcman, Alessandra Curioni-Fontecedro, Jarushka Naidoo, Adrianus J. de Langen, Lin Tao, Erica Su, Minoti Hiremath, Achim Rittmeyer, Melissa Johnson
Dual CD39 and PD-L1 inhibition: Interim results from the phase 2 MATISSE trial of IPH5201 plus durvalumab (durva) and platinum-based chemotherapy (CT) in patients (pts) with resectable NSCLC
Fabrice Barlesi, Tibor Csoszi, Renata Duchnowska, Thomas Egenod, Laurent Greillier, Amanda Psyrri, Maurice Perol, Herve Lena, Agnes Boyer-Chammard, Veronia Todary, Julien Viotti, Pascale André, Carine Paturel, Markus Jensen
Taletrectinib in tyrosine kinase inhibitor (TKI)-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC): Updated data from TRUST-I and TRUST-II
Geoffrey Liu, Jorge Nieva, Lyudmila Bazhenova, Chang-Min Choi, Qitao Yu, Shunichi Sugawara, Noriko Yanagitani, Filippo de Braud, Huijie Fan, Enriqueta Felip, Emilio Bria, Maurice Pérol, Feiwu Ran, Wei Wang, Xianyu Zhang, Michael Chen, Caicun Zhou
Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib
Geoffrey Liu, Alexander E. Drilon, Benjamin Besse, Gianluca Spitaleri, Jessica J. Lin, Byoung Chul Cho, Tatsuya Yoshida, Daniel Haggstrom, Steven Kao, Aurelie Swalduz, Misako Nagasaka, Benjamin J. Solomon, Lorenza Landi, Chiara Bennati, Elvire Pons-Tostivint, Christophe Dooms, A. J. van der Wekken, Saiama Waqar, Shirish Gadgeel, Chia-Chi Lin, Tetsuro Kondo, Hidetoshi Hayashi, Daniel Tan, Giulia Pasello, Matteo Duca, Luis G. Paz-Ares, Antonio Calles, Enriqueta Felip, Julien Mazieres, Adrianus Johannes de Langen, Alice T. Shaw, Jonathan W. Riess, Marina Garassino, Elaine Shum, Christina S. Baik, Jessica R. Bauman, D. Ross Camidge, Chien-Chung Lin, Gee-Chen Chang, Dong-Wan Kim, Myung-Ju Ahn, Ji-Youn Han, Kiichiro Ninomiya, Ryo Ariyasu, Ross Andrew Soo, Sanjay Popat, Jürgen Wolf, Maria Rosario García Campelo, Vivek A. Upadhyay, Stephen V. Liu
OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Primary Results of SARON: A Randomised-Controlled Trial of Consolidation Radiotherapy for Synchronous Oligometastatic Non-Small Cell Lung Cancer @fifimcdrmh 🫁 Randomized phase II (n=140): first-line SACT ± consolidation radiotherapy in synchronous oligometastatic AGA-negative NSCLC. Endpoints: OS and PFS. ➡️ Median OS 31.0 vs 28.0 mo; HR 0.99 (0.63–1.55); p=0.95 ➡️ Median PFS 13.9 vs 8.9 mo; HR 0.64 (0.43–0.95); p=0.03 ➡️ 12-month local failure 13.0% vs 39.5% (p<0.01); grade ≥3 AEs 28.6% in both arms ✅ SACT + RT achieved better local disease control and longer PFS with acceptable side effects, but this did not translate into survival benefit. 🎙️ Fiona McDonald (4Sight Made from Abstracts publicly available at the ESMO website) Pinging our OncoAlert Lung Cancer Faculty @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers
🔬ESMO 2026 Lung Cancer Abstract Highlights | How are emerging therapies reshaping the lung cancer treatment landscape? These 10 selected phase III studies explore new strategies across #SCLC and #NSCLC, including immunotherapy, next-generation #ADCs and targeted approaches to treatment resistance. 🔹DeLLphi-305 (LBA3): Tarlatamab + durvalumab vs. durvalumab alone as first-line maintenance for ES-SCLC, testing DLL3-directed T-cell engagement earlier in treatment. 🔹OptiTROP-Lung06 (LBA66): Sacituzumab tirumotecan (TROP2 ADC) + pembrolizumab vs. chemotherapy + pembrolizumab in first-line PD-L1-negative advanced nonsquamous NSCLC. 🔹OptiTROP-Lung04 (LBA67): Final overall survival analysis of sacituzumab tirumotecan vs. platinum-based chemotherapy after EGFR-TKI progression in EGFR-mutated NSCLC. 🔹Sigvotatug Vedotin (LBA68): A phase III comparison with docetaxel in previously treated nonsquamous NSCLC, examining efficacy and safety. 🔹KRASCENDO 1 (LBA5): Divarasib vs. sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC, offering a direct comparison within the targeted therapy class. 🔹SAFFRON (LBA6): Osimertinib + savolitinib vs. platinum-pemetrexed after osimertinib progression in EGFR-mutated NSCLC with MET overexpression and/or amplification. 🔹SANOVO (LBA69): Savolitinib + osimertinib vs. osimertinib alone in treatment-naïve EGFR-mutated NSCLC with MET overexpression, exploring upfront dual-target inhibition. 🔹PANKU-Lung01 (LBA71): Izalontamab brengitecan, a bispecific ADC, in EGFR-mutated nonsquamous NSCLC after progression on a third-generation EGFR-TKI. 🔹HERON-Lung01 (LBA72): Ruzaltatug rezetecan, a HER3-directed ADC, vs. platinum-based chemotherapy after EGFR-TKI progression in EGFR-mutated advanced NSCLC. 🔹Neotorch (LBA64): Final analysis of perioperative toripalimab + chemotherapy in resectable stage II-III NSCLC, focusing on long-term outcomes. 🔗Read more: https://oncodaily.com/oncolibrary/lung-oncology/esmo-2026-lung 💡MedChemExpress offers 3900+ tools for lung cancer research: https://www.medchemexpress.com/disease-areas/lung-cancer.html #ESMO26 #ESMO2026 #ESMO #LungCancer #CancerResearch #Oncology